BioNTech is expected to lead the market with projected sales of $885 million and a 44.6 per cent share by 2029. Melanoma remains the primary focus of advanced mRNA-based therapies, with promising results in Phase II trials., BioNTech is expected to lead the market with projected sales of $885 million and a 44.6 per cent share by 2029. Melanoma remains the primary focus of advanced mRNA-based therapies, with promising results in Phase II trials., , Read More
AAS Yoga
Go for Euphoria – Illness to Wellness the Natural Way